Expansion of Growth Areas through Strategic M&A

「The company acquired ETG Global Information Technology Services Inc. in March 2026. By combining the company's established business platform with ETG's technological capabilities and IT talent base, it will expand its core systems sales and implementation support business globally.」

「In the Business Solutions segment, sales increased, mainly due to growth in sales of services to local governments and DX-related solutions driven by replacement demand associated with the end of Windows 10 support. In February 2025, the company completed the acquisition of パシフィックビジネスコンサルティング, which provides implementation consulting services for Microsoft Dynamics 365. By strengthening its business platform for selling and supporting the implementation of core systems for mid-sized and small and medium-sized companies through this acquisition, the company will further grow its core business.」

「Sales increased, supported by the semiconductor process chemicals business acquired from U.S. company Entegris in October 2023.」

「In the Electronic Materials segment, although results were affected by the downturn in semiconductor market conditions, sales were broadly in line with the same period of the previous year, supported by the semiconductor process chemicals business acquired from U.S. company Entegris in October 2023.」

「On 2 October 2023 (U.S. Eastern Standard Time), the company acquired all issued shares of CMC Materials KMG Corporation, a group company of U.S. semiconductor materials manufacturer Entegris, Inc. that operates a global semiconductor process chemicals business, for approximately US$700 million, making it a wholly owned subsidiary to accelerate growth in the electronic materials business.」

「In the Business Solutions segment, sales increased, mainly due to higher domestic sales to local governments and the contribution of Australian company MicroChannel Services, which was acquired in fiscal 2022.」

「To accelerate growth in its electronic materials business, the company entered into a share purchase agreement on 10 May 2023 to acquire all issued shares of CMC Materials KMG Corporation, a Group company of US semiconductor materials manufacturer Entegris.Inc that operates a global semiconductor process chemicals business, for US$700 million.」

「In December 2022, the company announced the acquisition of the digital pathology business of US-based Inspirata, Inc., which develops and sells software for digital pathology diagnosis, among other products.」

「In July 2022, the company acquired UNIGRAPHICA AG, a leading European systems integrator specializing in customized inkjet system offerings, to further expand its inkjet business in Europe.」

「FUJIFILM Corporation acquired a manufacturing site for cell therapy drugs from US biotechnology venture Atara Biotherapeutics, Inc. for approximately US$100 million. It also acquired Shenandoah Biotechnology, Inc., a US biotechnology company engaged in the development, manufacture and sale of cytokines that promote cell proliferation, differentiation and functional expression.」

「On 1 January 2022, HOYA Digital Solutions Co., Ltd., whose acquisition had been completed, began operations under the new name FUJIFILM Digital Solutions Co., Ltd.」

「On 31 March 2021, the acquisition of Hitachi, Ltd.'s diagnostic imaging business was completed, and Fujifilm Healthcare Co., Ltd., which inherited the business, began operations as a new Group company.」

「To further expand its healthcare business, FUJIFILM Corporation, a wholly owned subsidiary of the company, will acquire Hitachi, Ltd.'s diagnostic imaging business. On 18 December 2019, the company entered into an agreement under which Fujifilm would acquire all shares of a new company from Hitachi, Ltd.」

「In December 2019, the company announced the acquisition of Hitachi, Ltd.'s diagnostic imaging business. Through this acquisition, the company will provide a broader range of higher-quality solutions, play an advanced role in improving the quality of healthcare, and establish a business foundation as one of the world's leading healthcare companies.」

「In August 2019, the company completed the acquisition of Biogen (Denmark) Manufacturing ApS, a manufacturing subsidiary of major biopharmaceutical company Biogen Inc.」

「FUJIFILM Corporation, a wholly owned subsidiary of the company, acquired all equity interests in Biogen (Denmark) Manufacturing ApS, a manufacturing subsidiary of major US biopharmaceutical company Biogen Inc., on 1 August 2019 to further expand its biopharmaceutical development and contract manufacturing business. The acquisition cost was approximately US$890 million.」

「In May 2019, we announced the acquisition of medwork, a company engaged in the development, manufacture, and sale of endoscopic treatment devices, marking our full-scale entry into the endoscopic treatment device business.」

「In March 2019, FUJIFILM Corporation entered into an agreement to acquire all equity interests in Biogen (Denmark) Manufacturing ApS, a manufacturing subsidiary of major US biopharmaceutical company Biogen Inc., to further expand its biopharmaceutical development and contract manufacturing business.」

「FUJIFILM Holdings America Corporation and FUJIFILM Corporation, both wholly owned subsidiaries of the company, made Irvine Scientific Sales Company, Inc. and ㈱アイエスジャパン, leading companies in media required for cell culture, wholly owned subsidiaries on 1 June 2018 to achieve further growth in the healthcare business.」

「In March 2018, FUJIFILM Corporation entered into a share purchase agreement to acquire all issued shares of ISUS and ISJ, leading companies in media required for cell culture, and completed the acquisition in June 2018.」

「• Fuji Xerox will acquire as treasury shares 75% of the total number of issued shares of Fuji Xerox held by the company, enabling Xerox, which held 25% of Fuji Xerox's total issued shares, to make Fuji Xerox a wholly owned subsidiary. • Subsequently, the company will acquire 50.1% of Xerox's shares by subscribing to a third-party allotment of new shares by Xerox, using the consideration received from Fuji Xerox's treasury share acquisition.」

「In addition, the company will establish an investment budget of ¥500 billion over 3 years for strategic M&A and aims to achieve further revenue and profit growth.」

「In the fine chemicals business, Wako Pure Chemical Industries Co., Ltd. became a consolidated subsidiary in April 2017, establishing a reagents and chemicals business with a strong operating base. The Group will strengthen integration across the organization to realize synergies with Wako Pure Chemical Industries Co., Ltd. at an early stage and accelerate business growth.」

「In April 2017, Wako Pure Chemical Industries Co., Ltd., which has advanced technologies in media and cytokines that play important roles in regenerative medicine, was added to the Group.」

「Fujifilm, our wholly owned subsidiary, decided at its Board of Directors meeting on 15 December 2016 to acquire the common shares of Wako Pure Chemical Industries through a tender offer under the Financial Instruments and Exchange Act (Act No. 25 of 1948, as amended). Going forward, the company aims to achieve further growth in its healthcare and high-performance materials businesses by creating synergies with Wako Pure Chemical Industries, maximizing existing businesses, and developing and providing highly competitive new products.」

「In the in vitro diagnostics (IVD) field, the company acquired ㈱モノリス in August 2016 and entered the contract testing services business for animal specimens.」

「In addition to sales expansion activities and the launch of new products, we will also use strategic M&A to accelerate the expansion of revenue, market share and profit.」